AngioScore

About AngioScore

AngioScore Inc. was established in 2003 by co-founders Eitan Konstantino and Gary Gershony, positioning itself as a key developer of specialized medical devices for endovascular therapy. Konstantino, who served as president and chief scientist until 2006, was the primary inventor of the company's core technology. Gershony, a practicing interventional cardiologist, brought deep clinical expertise to the venture as chief medical officer. Based in Fremont, California, the company focused on designing, manufacturing, and marketing scoring balloon catheters to treat cardiovascular diseases.

The company's flagship product line, the AngioSculpt Scoring Balloon Catheters, was developed to address both peripheral arterial disease (PAD) and coronary artery disease (CAD). This device features a flexible nitinol scoring element that precisely scores plaque within an artery, allowing for controlled and predictable vessel dilatation. The product portfolio included the AngioSculpt PTCA for coronary arteries and the AngioSculpt PTA for peripheral arteries, treating lesions in various locations such as the iliac, femoral, and popliteal arteries. The catheters gained initial FDA 510(k) clearance in 2005, with subsequent approvals expanding their application, including for treating complex in-stent restenosis.

AngioScore's business model revolved around the direct sale and distribution of these single-use medical devices to hospitals and catheterization labs. The company established a direct sales force in the United States and utilized a network of distributors to market its products in over 60 countries. Before its acquisition, AngioScore had raised approximately $90 million in funding through several rounds from investors including Saints Capital and Telegraph Hill Partners. In a significant milestone, Spectranetics Corporation acquired AngioScore on June 30, 2014, for an upfront payment of $230 million, with potential for additional milestone-based payments. The acquisition aimed to combine two fast-growing companies to broaden the treatment options for complex cardiovascular conditions like critical limb ischemia (CLI) and calcified lesions.